Baines AC - Search Results

1

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.

Baines AC, Ershler R, Kanapuru B, Xu Q, Shen G, Li L, Ma L, Okusanya OO, Simpson NE, Nguyen W, Theoret MR, Pazdur R, Gormley NJ. Baines AC, et al. Clin Cancer Res. 2022 Nov 1;28(21):4629-4633. doi: 10.1158/1078-0432.CCR-22-0618. Clin Cancer Res. 2022. PMID: 35736811 Free PMC article.

2

Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.

Voorhees PM, Jakubowiak AJ, Kumar SK, Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley NJ, Pazdur R. Voorhees PM, et al. Among authors: baines ac. Clin Cancer Res. 2022 Jan 1;28(1):23-26. doi: 10.1158/1078-0432.CCR-21-1069. Epub 2021 Jul 27. Clin Cancer Res. 2022. PMID: 34315721

3

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.

Kanapuru B, Fernandes LL, Fashoyin-Aje LA, Baines AC, Bhatnagar V, Ershler R, Gwise T, Kluetz P, Pazdur R, Pulte E, Shen YL, Gormley N. Kanapuru B, et al. Among authors: baines ac. Blood Adv. 2022 Mar 22;6(6):1684-1691. doi: 10.1182/bloodadvances.2021005482. Blood Adv. 2022. PMID: 35114691 Free PMC article.

4

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.

Baines AC, Yazdy MS, Kasamon YL, Ershler R, Jen EY, Kanapuru B, Richardson NC, Lane A, Carioti T, Theoret MR, Pazdur R, Gormley NJ. Baines AC, et al. Clin Cancer Res. 2023 Aug 1;29(15):2748-2752. doi: 10.1158/1078-0432.CCR-22-3579. Clin Cancer Res. 2023. PMID: 36892497 Free PMC article.

5

Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.

Kanapuru B, Fernandes LL, Baines A, Ershler R, Bhatnagar V, Pulte E, Gwise T, Theoret MR, Pazdur R, Fashoyin-Aje L, Gormley N. Kanapuru B, et al. Blood. 2023 Jul 20;142(3):235-243. doi: 10.1182/blood.2022018657. Blood. 2023. PMID: 37140031 Free article.

6

FDA Approval Summary: Teclistamab - A Bispecific CD3 T-cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.

Baines AC, Kanapuru B, Zhao J, Price LSL, Zheng N, Konicki R, Manning ML, Gehrke BJ, Theoret MR, Gormley NJ. Baines AC, et al. Clin Cancer Res. 2024 Oct 16. doi: 10.1158/1078-0432.CCR-24-1872. Online ahead of print. Clin Cancer Res. 2024. PMID: 39412823

7

Receptor-mediated protein transport in the early secretory pathway.

Baines AC, Zhang B. Baines AC, et al. Trends Biochem Sci. 2007 Aug;32(8):381-8. doi: 10.1016/j.tibs.2007.06.006. Epub 2007 Jul 6. Trends Biochem Sci. 2007. PMID: 17618120 Review.

8

Mice deficient in LMAN1 exhibit FV and FVIII deficiencies and liver accumulation of α1-antitrypsin.

Zhang B, Zheng C, Zhu M, Tao J, Vasievich MP, Baines A, Kim J, Schekman R, Kaufman RJ, Ginsburg D. Zhang B, et al. Blood. 2011 Sep 22;118(12):3384-91. doi: 10.1182/blood-2011-05-352815. Epub 2011 Jul 27. Blood. 2011. PMID: 21795745 Free PMC article.

9

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.

Chen XW, Wang H, Bajaj K, Zhang P, Meng ZX, Ma D, Bai Y, Liu HH, Adams E, Baines A, Yu G, Sartor MA, Zhang B, Yi Z, Lin J, Young SG, Schekman R, Ginsburg D. Chen XW, et al. Elife. 2013 Apr 9;2:e00444. doi: 10.7554/eLife.00444. Elife. 2013. PMID: 23580231 Free PMC article.

10

Disruption of the Sec24d gene results in early embryonic lethality in the mouse.

Baines AC, Adams EJ, Zhang B, Ginsburg D. Baines AC, et al. PLoS One. 2013 Apr 15;8(4):e61114. doi: 10.1371/journal.pone.0061114. Print 2013. PLoS One. 2013. PMID: 23596517 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters